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Available online 28 October 2016Background: Diffuse gliomas, grades II and III, hereafter called lower-grade gliomas (LGG), have variable, difﬁcult
to predict clinical courses, resulting in multiple studies to identify prognostic biomarkers. The purpose of this
study was to assess expression or methylation of the homeobox family gene SHOX2 as independent markers
for LGG survival.
Methods:We downloaded publically available glioma datasets for gene expression and methylation. The Cancer
Genome Atlas (TCGA) (LGG, n= 516) was used as a training set, and three other expression datasets (n= 308)
and three other methylation datasets (n= 320), were used for validation.We performed Kaplan-Meier survival
curves and univariate and multivariate Cox regression model analyses.
Findings: SHOX2 expression and gene body methylation varied among LGG patients and highly signiﬁcantly pre-
dicted poor overall survival. While they were tightly correlated, SHOX2 expression appeared more potent as a
prognostic marker and was used for most further studies. The SHOX2 prognostic roles were maintained after
analyses by histology subtypes or tumor grade.We found that the combination of SHOX2 expression and IDH ge-
notype status identiﬁed a subset of LGG patients with IDHwild-type (IDHwt) and low SHOX2 expression with
considerably favorable survival. We further investigated the combination of SHOX2with other known clinically
relevantmarkers of LGG (TERT expression, 1p/19q chromosome co-deletion,MGMTmethylation, ATRXmutation
and NES expression). When combinedwith SHOX2 expression, we identiﬁed subsets of LGG patients with signif-
icantly favorable survival outcomes, especially in the subgroupwith worse prognosis for each individual marker.
Finally, multivariate analysis demonstrated that SHOX2was a potent independent survival marker.
Interpretation:We have identiﬁed that SHOX2 expression or methylation are potent independent prognostic in-
dicators for predicting LGG patient survival, and have potential to identify an important subset of LGG patients
with IDHwt status with signiﬁcantly better overall survival. The combination of IDH or other relevant markers
with SHOX2 identiﬁed LGG subsets with signiﬁcantly different survival outcomes, and further understanding of
these subsets may beneﬁt therapeutic target identiﬁcation and therapy selections for glioma patients.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Brain tumor gliomas include low grade (grade I) pilocytic astrocyto-
mas, and the diffuse gliomas that include the grades II and III astrocyto-
mas and oligodendrogliomas (referred to as lower-grade gliomas, LGG)
and the highly malignant grade IV glioblastomas [GBM, grade IV, the
World Health Organization (WHO) Classiﬁcation of Tumors of the
Central Nervous System (CNS)] (Louis et al., 2016; Louis et al., 2007).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
81Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89LGG are diffusely inﬁltrative tumors andhave highly variable, difﬁcult to
predict clinical courses, further compounded by inter-observer variabil-
ity in histologic classiﬁcation and grading (van den Bent, 2010; Louis et
al., 2007). While some LGG have indolent outcomes, others rapidly
progress to high grade GBM. GBM patients almost always die from
their disease (Louis et al., 2007; Ostrom et al., 2015). The evolution of
gliomas from grade II to grade III or IV are characterized by the stepwise
acquisition of genetic alterations and a considerable worsening of prog-
nosis, justifying studies to identify genetic alterations as potential bio-
markers for prognosis and selection of targeted therapy and overall
clinical management (Ellison, 2015). A relatively recent ﬁnding of
major biological and clinical importance was the identiﬁcation of muta-
tions in the isocitrate dehydrogenase (IDH) enzyme genes IDH1 and
IDH2. Somatic mutations, in particular of the IDH1 gene, are present in
the majority of LGG, especially oligodendrogliomas, and have a positive
effect on overall survival (Turkalp et al., 2014; Yan et al., 2009). They are
rare in primary GBM and absent in pilocytic astrocytomas and are often
associated withMGMT promoter hypermethylation, TP53mutations as
well as co-deletions of chromosome 1p or 19q (1p/19q codel). IDHmu-
tations are an early, possibly driver, event for LGG (Watanabe et al.,
2009), and clinical trials of IDH inhibitors are underway (Dimitrov etSHOX2
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Fig. 1. Identiﬁcation and correlation of differential SHOX2methylation and expression in glial tu
BeadChip (Illumina) array (450 K) were based on the UCSC Genome Browser (http://genom
designated 450 K probes are indicated by vertical lines scattered throughout SHOX2 gene (N
TCGA LGG and GBM 450K datasets). (B) Differential SHOX2 methylation among non-mal
glioblastomas (GBM) using TCGA LGG and GBM 450 K datasets. Five high differential methyla
Fig. 1A) was used. (C) Differential SHOX2 mRNA expression using GSE16011 microarray data
SeqV2 datasets (see also Appendix p2–9 for dataset source and data analyses). r: Spearman r,al., 2015). Many studies have demonstrated that survival outcome of
LGG patients is signiﬁcantly different based on the status of IDH gene
mutation, 1p/19q codeletion, telomerase reverse transcriptase (TERT)
promotermutation,ATRX genemutation, CpG islandmethylator pheno-
types (CIMP), O-6-methylguanine-DNAmethytransferase (MGMT) pro-
moter methylation, the neural stem cell gene nestin (NES) expression
and mRNA expression signatures by multiple genes (Cancer Genome
Atlas Research et al., 2015; Eckel-Passow et al., 2015; Ceccarelli et al.,
2016; Chan et al., 2015; Noushmehr et al., 2010; Turcan et al., 2012;
Hatanpaa et al., 2014; Siegal, 2015; Bao et al., 2014; Zhang et al.,
2015). The classiﬁcation by CIMP status after ﬁltering IDHmutation sta-
tus revealed biologically discrete subsets having different clinic survival
outcomes in diffuse gliomas (Ceccarelli et al., 2016), supporting the
principle that IDH mutation status plus other molecular biomarkers
can enhance the prognostic value for certain molecularly distinct sub-
sets of LGG patients. The importance of combining tumormolecular fea-
tures with traditional diagnostic features such as histology and grading
was recognized in the recently revised 2016WHOclassiﬁcation systems
of CNS tumors (Louis et al., 2016).
The SHOX2 gene, located on chromosome 3q, is a member of the ho-
meobox family of genes that encodes a transcriptional regulator and itshg19
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82 Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89expression is highly restricted to craniofacial, brain, heart, and limb de-
velopment (Blaschke et al., 1998; Clement-Jones et al., 2000). SHOX2
promoter DNA methylation has been identiﬁed as a diagnostic and
prognostic biomaker for non-small cell lung cancer patients (Schmidt
et al., 2010; Dietrich et al., 2012). Elevated SHOX2 expression is associat-
ed with tumor recurrence of hepatocellular carcinoma (Yang et al.,
2013) and with poor survival in breast cancers (Hong et al., 2014). In
our experience, some genes such as SCT and ITPKA, are frequentlymeth-
ylated in many invasive cancers, but their methylation in certain low-
grade tumors is variable (Zhang et al., 2016; Wang et al., 2016). The
availability of a well-studied large set of LGG having molecular data in-
cluding exome sequencing and genome wide methylation (Cancer
Genome Atlas Research et al., 2015), permitted us to examine the prog-
nostic role of SHOX2methylation and expression in gliomas and to cor-
relate the data with other prognostic parameters. The primary aim of
our studywas to demostrate the prognostic role of SHOX2 as a single in-
dicator or in combination with IDH and other biomakers for improving
survival predictions for LGG patients.
2. Materials and Methods
2.1. Datasets
We examined publically available genome-wide methylation and
expression data of nonmalignant brains and glioma tissues, the associat-
ed pathological molecular markers, and clinical variables from the fol-
lowing main sources: The Cancer Genome Atlas (TCGA) data portal,
National Center for Biotechnology Information (NCBI) Gene Expression
Omnibus (GEO), ArrayExpress, and the data as described previously
(Ceccarelli et al., 2016). The detailed list of data sources and accession
dates and data process are provided in Appendix p1–4.
We used the TCGA LGG dataset as a training set to study the associ-
ation between SHOX2methylation (or expression) and overall survival
in LGG patients. These ﬁndings were independently validated in three
external expression microarray datasets (GSE16011, GSE30336 and
REMBRANDT) and three external methylation datasets (GSE61160,
GSE30338 and GSE58218). Details of the clinical trials and cancerFig. 2.Kaplan-Meier survival curve analyses of SHOX2 alone and the combination of SHOX2with
methylation (cutoff value of 0.357) and RNA-Seq expression data (cutoff value of 4.135) we
mutation (see also Appendix p2–9 for dataset source and data analyses).centers from which the data were extracted are provided in Appendix
p3–4. We examined enhanced prognostic values of SHOX2 in subsets
of LGG classiﬁed by IDH or other known relevant markers using TCGA
LGG datasets.
2.2. Statistical analysis
Two-tailed, Student t-test was performed to compare two groups of
numerical values. To assess SHOX2 as a prognostic biomarker, patient
samples analyzed were dichotomized into two groups designed as
high- and low- groups, based on a SHOX2 cutoff value for their methyl-
ation or expression values. For the dataset containing numerical values,
we used a data-driven approach to deﬁne an objective cutoff value by
using model-based clustering method implemented by “mclust” pack-
age version 4.4 for R (Fraley and Raftery, 2002). By mclust clustering
analysis, the SHOX2 values (methylation or expression) were ﬁtted
into a mixture of two normal distributions, onewith high SHOX2 values
and the other with low SHOX2 values. The same approach was used to
deﬁne the cutoff value for younger and older patient groups by age.
Overall survival time was calculated from the date of diagnosis until
death or the last follow-up contact. Survival curves were estimated
using the product-limit method of Kaplan-Meier (Kaplan and Meier,
1958) with the log-rank test. Univariate and multivariate Cox tests
were performed to assess the relative contribution of the risk group
when assessed alone or after adjusting for clinical variables (or other in-
dicator) (Andersen and Gill, 1982, Therneau and Grambsch, 2000).
3. Results
3.1. SHOX2 Methylation or mRNA Expression in Glial Tumors
A cartoon anddescription of the SHOX2gene are presented in Fig. 1A.
From the TCGA datasets, varying degrees of methylation were noted at
the 35 probes covering the entire gene (Fig. 1). We identiﬁed ﬁve
probes, named as P1, P2, P8, P9 and P10 (Fig. 1A) which showed signif-
icantly high differential methylation in glial tumors (see details on Ap-
pendix p5–9). These probes were located between the last two exonsIDHmutation status in LGGpatients using TCGA LGGdatasets. The analyses of SHOX2450K
re presented in Figs. 2B1-3 and C1–3, respectively. IDHwt: IDH wild-type; IDHmut: IDH
AB
Fig. 3. The univariate Cox proportional-hazards model survival analyses of SHOX2 and other individual markers (A), and SHOX2 expression marker in the subsets for LGG patients when
combinedwith other individualmarkers (B) using TCGA LGG datasets. (A) Comparison of SHOX2markerwith other individual markers. (B) Comparison of enhanced prognostic values of
SHOX2 expression marker in the subsets of LGG sub-classiﬁed by other individual markers. Note: NES expression was dichotomized into high- (N13.35) and low- (≤13.35) subgroup by
usingmedian RNA-Seq value of 13.35 instead of themclust clustering determined cutoff value (11.31) due to in part that the latter cutoff value resulted in a small number of samples (n=
30) for NES expression low subset with less statistical power in further analyses. HR: hazard ratio. NA: not available.
83Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89and not at CpG island sites. As shown in Fig. 1B, SHOX2methylationwas
absent or low in non-malignant brain tissues and pilocytic astrocytomas
(PA), frequent and high in GBM, andwith intermediate frequencies and
values in LGG, respectively.O
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Fig. 4. Kaplan-Meier overall survival curve analyses of SHOX2methylation in additional exte
analyses were performed using SHOX2 pooled mean methylation probe values (see Fig. 1) of
See Appendix p2–4, 13–14 for detailed list of datasets and data source and further analyses daBy microarray data, SHOX2 expression patterns were similar to
methylation: low in non-malignant brain and PA cases, high in GBM
and intermediate but variable in LGG (Fig. 1C). The signiﬁcantly higher
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Fig. 5. Comparison of SHOX2 methylation by IDH mutation or CIMP status in additional
external 450K methylation dataset besides the TCGA LGG dataset. The SHOX2 pooled
mean beta value of four probes (Probes 1, 2, 8 and 9, Fig. 1A) was used, (GSE58218
dataset) were used and compared by IDHmutation or CIMP status. Bars: median values.
wt: wild type; mut: mutation; unk: unknown. p: t-test. See Appendix p2–4 for detailed
list of datasets and data source.
84 Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89validated in additional microarray datasets (Appendix p10). The RNA-
Seq data showed the same pattern of differential SHOX2 expression
(Fig. 1D). In addition, by correlating the RNA-Seq data with theirSHOX2mRNA_Low (n=104)
SHOX2mRNA_High (n=47)
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Fig. 6. Kaplan-Meier overall survival curve analyses of SHOX2 expression in additional external
SHOX2 mRNA expression were determined by mcluster analysis of datasets (see Materials/M
REMBRANDT (C): 6.575, respectively]. Note: IDHmutation status was classiﬁed based on IDH
detailed list of datasets and data source and further analyses data.corresponding sample methylation data available, we found that the
SHOX2methylation and RNA-Seq expression values were highly posi-
tively correlated in both LGG and GBM tumors (Fig. 1D).3.2. SHOX2 Methylation and mRNA Expression are Independent Potent
Prognostic Markers for LGG
To explore whether SHOX2methylation and expression are related
to LGG patient survivals, we ﬁrst analyzed TCGA LGG training datasets
containing 516 cases. The samples were dichotomized into either high
or low subgroups when classiﬁed by SHOX2 methylation or mRNA ex-
pression levels. We found that the methylation marker based on any
of the ﬁve differentially methylated probes alone predicted overall sur-
vival of LGG patients, and use of the pooled mean beta values of four
probes (Probes 1, 2, 8 and 9, Fig. 1A) showed signiﬁcantly improved
prognostic values as compared with the use of individual probes (Ap-
pendix p11–12) and other varied combinations of these probes (not
shown). Thus the pooledmean beta valueswere used for further surviv-
al analyses of SHOX2 methylation. Our analyses demonstrated that
SHOX2 methylation was associated with poor survival prognosis and
was a potent independent prognosis marker for LGG [Figs. 2B1 and
3A, hazard ratio (HR) 3.33 (95% CI 2.33 to 4.76), p = 3.45E-12]. SHOX2
highmethylation predicted a poor overall survival of LGG patients com-
parable to IDH mutation status, and was signiﬁcantly correlated with
CIMP-negative marker, a poor survival prognosis marker for LGG
(Wiestler et al., 2014; Noushmehr et al., 2010) as demonstrated in25
0 2 4 6 8
IDHwt_SHOX2_Low (n=6)
IDHwt_SHOX2_High (n=6)
p=0.0467
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mRNAmicroarray expression datasets besides the TCGA LGG dataset. The cutoff values of
ethods) [SHOX2 mRNA probe_210135_s_at: GSE16011(A): 5.922; GSE30336 (B): 5.678;
1 (R132) mutation status available in GSE16011 dataset. See Appendix p2–4, 15–16 for
85Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89three independent external 450 K methylation datasets (Figs. 4–5 and
Appendix p13–14). SHOX2 methylation (of the gene body associated
with increased gene expression) was negatively correlated with CIMP
status (methylation of promoter region of multiple genes associated
with suppression of gene expression) (Fig. 5).
Similarly, SHOX2 high mRNA expression (SHOX2_high) was an even
more potent independentmarker in predictingworse overall survival in
the same LGG dataset using TCGA LGG RNA-Seq dataset [n = 516, HR
5.08 (95% CI 3.53 to 7.33), p b 2.0E-16] (Fig. 2C1, Fig. 3A). These ﬁndings
were independently validated in three additional external expression
microarray datasets, as demonstrated by using SHOX2 as a single prog-
nosticmarker or in combination of SHOX2with IDH status data available
(Fig. 6 and Appendix p15–16).
While SHOX2 methylation and expression were highly correlated,
SHOX2 expression appeared more potent than methylation for
predicting LGG survival and complete expression datasets were more
widely available. For these reasons above, we used SHOX2 expression
marker for further studies.
We observed that SHOX2 expression marker had a prognostic value
comparable to IDH status marker, a widely-accepted potent prognostic
marker for LGG [IDH wild type (IDHwt) vs mutant type (IDHmut) HR
6.52 (95%CI 4.49 to 9.47), p b 2.0E-16] (Figs. 2A, C1 and 3A). Interesting-
ly, there was a signiﬁcantly higher concordance rate (0.75) between
IDHmut and SHOX2 low expression than that (0.05) between IDHwt
and SHOX2 low expression, as compared with a signiﬁcant but less de-
gree concordance difference between IDHwt and SHOX2 high expres-
sion (0.13) vs SHOX2 low expression (0.06) using TCGA LGG
expression dataset (Appendix p17). As compared with other known
markers, such as TERT, MGMT, 1p/19q codel, TERT and NES, SHOX2 had
the highest prognostic hazard ratio value as demonstrated in the uni-
variate Cox proportional-hazards model analyses of each marker as a
single indicator in TCGA LGG dataset (Fig. 3A).Years Sinc
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Fig. 7. Kaplan-Meier overall survival curve analyses of SHOX2 expression in LGG by histology a
(4.135) was used to determine SHOX2 expression high vs low. The grades II or III tumor samp
Appendix p2–4, 18 for detailed list of datasets and data source and further analyses data.We performed overall survival analyses of SHOX2 expression by his-
tology (astrocytoma, oligodendroglioma, excluding oligoastrocytoma
which is not recognized as a separate entity in the 2016 CNS tumor clas-
siﬁcation system) (Louis et al., 2016) or tumor grade (grades II and III).
We found that SHOX2 expressionwas a potent survival indicator in both
histology types and grades, especially in astrocytoma and grade III tu-
mors (Fig. 7 and Appendix p18).
However, we did not ﬁnd that SHOX2 expression was a prognostic
marker for overall survival in high grade GBM patients in TCGA GBM
dataset (Appendix p19), possibly because the vast majority of GBM
samples had high SHOX2 expression values (Fig. 1D).
3.3. Combination of SHOX2 with IDH and Other Relevant Prognostic
Markers
Next, we determinedwhether SHOX2 can improve prognostic values
of IDH in LGG patients. While the poor prognostic SHOX2_high and
IDHwt subgroups were frequently present together (Appendix p20),
we found that approximately one third (27 out of 94) of the IDHwt
cases which had SHOX2 low expression, were associated with an im-
proved overall median survival of 9.6 years (p = 7.29E-05, log-rank
test) (Figs. 2C2 and 3B). By contrast, combining SHOX2 expression or
methylation had no or minimal effect on the favorable prognostic
IDHmut subgroup.
The ﬁndings of the enhanced prognostic combination of SHOX2 and
IDHmarkers led us to further study whether SHOX2 can aid the prog-
nostic values of other LGG prognostic markers (NES expression,MGMT
methylation, TERT promoter mutation or expression, 1p/19q codel and
ATRXmutation). Using the TCGA dataset, we analyzed each marker by
itself, and compared with the prognostic values of SHOX2 marker in
the dichotomized subsets of LGG by these individual markers (Figs. 3B
and 8). We found that 1p/19q codel orMGMTmethylation as individuale Diagnosis
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86 Y.-A. Zhang et al. / EBioMedicine 13 (2016) 80–89markers had a moderate prognostic effect, and NES, TERT and ATRX
marker had no signiﬁcant prognostic effect. In particular, we found
that SHOX2 expression identiﬁed favorable prognostic subsets more
signiﬁcantly in the unfavorable prognosis subgroup determined by
each individual marker, which was similar to our ﬁndings in the subset
of IDHwt LGG (Figs. 3 and 8).SHOX2
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improved in combination with IDH mutation status, as compared to
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when combined with other individual markers (TCGA LGG dataset). This ﬁgure presented
ually, and SHOX2 expression marker in the subsets of LGG sub-classiﬁed by these other
determine SHOX2 expression high vs low. See Appendix p2–4 for detailed list of datasets
analyzed.
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a degree similar and comparable to IDHmutation status marker (Fig. 3B
and Appendix p21).3.4. Multivariate Cox Proportional-hazards Survival Analysis of SHOX2 and
Other Markers
We performed multivariate Cox regression survival analysis to as-
sess the relative contribution of the predicted risk groups classiﬁed by
SHOX2 expression, after adjusting for clinical variables including age,
gender, stage and histology subtypes as well as other prognostic
markers. We demonstrated that SHOX2 expression and age were highly
signiﬁcant independent variables, while, gender, histology and tumor
grade were of lesser signiﬁcance (Table 1). Both SHOX2 methylation
and expression remained a signiﬁcantly predictive marker and SHOX2
expression had a stronger prognostic value comparable to IDH [methyl-
ation: HR 1.65 (95% CI 1.08 to 2.50, p = 1.94E-02); expression: HR 3.38
(95% CI 2.25 to 5.09, p = 5.12E-09; IDH: HR 3.82 (95% CI 2.47 to 5.90),
p = 5.12E-09)] (Table 1 and Fig. 9).
To determine the relative contribution of the risk groups by SHOX2
marker, after adjusting for the status of other known markers, we per-
formed multivariate analyses under the same clinical variables setting
as shown in Table 1 except including one of other prognostic markers
(IDH, 1p/19q codel, TERT, MGMT, NES and ATRX) (Fig. 9). Fig. 8 shows
a comparison of the hazard ratio values of SHOX2 marker vs. other
markers by multivariate analyses, and we demonstrated that under
the combination of SHOX2 with the other prognostic markers, SHOX2
was also an independent prognostic factor. By contrast, IDH, 1p/19q
codel andMGMT but not TERT andNES showedmoderate prognostic sig-
niﬁcance after adjusting by SHOX2 marker, based on their HR and p
values (Fig. 9).
The overall survival of LGG patients was previously reported to be
related with age and histology (Turcan et al., 2012; Cancer Genome
Atlas Research et al., 2015) We found that SHOX2 high methylation
and expression were associated with astrocytoma histology type (Ap-
pendix p22). SHOX2 methylation and expression levels were low and
not age-dependent in normal and non-malignant brain tissues (Appen-
dix p23–24), but appeared partially age-dependent in LGG tumors as
reﬂected by a subset of LGG cases with high SHOX2methylation and ex-
pression values available in all age groups. Thusweperformedmultivar-
iate analyses in younger (b48 years) or older (≥48 years) subgroups,
respectively. The cutoff value (48 years) was objectively determined
by model based clustering analysis of age data in TCGA LGG dataset
(see Methods Statistical analysis). We found that IDH and SHOX2 ex-
pression as individual markers both had higher HR values in the older
patient subgroup than those in young patient subgroup, and SHOX2
had a slightly higher HR value with a higher signiﬁcant p value than
IDH in the younger patient subgroup [SHOX2: HR 3.00 (95% CI 1.54 to
5.87), p = 0.0013; IDH: HR 2.65 (95% CI 1.19 to 5.90), p = 0.0171] (Ap-
pendix p25). While both SHOX2 and IDHwere included in multivariate
analyses, SHOX2 was more signiﬁcant than IDH in the younger patientTable 1
The multivariate Cox proportional-hazards models analyses of SHOX2methylation or expressio
Variable
SHOX2 methylation
Hazard ratio (95% CI)
Patient#/Event#: 512/126
SHOX2 high vs low 1.65 (1.08 to 2.50)
Age 1.06 (1.04 to 1.07)
Gender (male vs female) 1.14 (0.79 to 1.64)
Histology (OA vs A) 0.65 (0.40 to 1.05)
Histology (OD vs A) 0.51 (0.33 to 0.78)
Tumor Grade (3 vs 2) 2.10 (1.37 to 3.23)
Hazard ratio for age variable: risk per 1 year. OA: oligoastrocytoma; A: astrocytoma; OD: oligo
See Appendix p3–4 for sample source and data.subgroup. The results of comparing SHOX2with othermarkers in differ-
ent age subgroups are presented in (Appendix p25–27).4. Discussion
In May of 2016, the latest version of 2016 WHO Classiﬁcation was
published, and the major changes in this version, as it relates to the
present report, was combining molecular markers with traditional
histology classiﬁcation to introduce a more clinically relevant classiﬁca-
tion (Louis et al., 2016). In particular, a) most grades II and III diffuse
gliomas have mutations in IDH1 or IDH2 genes; 2) most astrocytomas
are 1p/19q intact and are often ATRX and TP53 mutant; 3) most or all
oligodendrogliomas are 1p/19q co-deleted; and 4) combined
oligoastrocytomas are no longer recognized as an entity, but should
be reclassiﬁed based on their molecular features. The grading system
is maintained but its importance is de-emphasized. We present
our analyses using traditional histology (omitting the category
oligoastrocytoma) and grading, and the various molecular analyses in-
cluding IDH, ATRX mutation status and 1p/19q co-deletions. The
datasets we utilizedwere generated prior to the revised 2016 Classiﬁca-
tion, and from the sample data available, not all cases can be reclassiﬁed.
We did not combine the traditional methods (histology and grading)
with molecular methods for comparison with SHOX2 expression or
methylation, as that would introduce too many variables and would re-
sult in subsets that could not be reclassiﬁed according to the 2016 Clas-
siﬁcation. However, because our approach utilized both the traditional
approaches and the important molecular features utilized in the 2016
Classiﬁcation (IDH and ATRX mutation status, and 1p/19q co-deletion
status) we believe it is relevant to the new 2016 WHO classiﬁcation.
The role of multiple prognostic markers has been investigated in
LGGs. We investigated the role of SHOX2 expression and methylation
in LGGs and their relationship to other prognostic and pathologic
markers. We found approximately 20% of tumors had increased levels
of expression and/or methylation. There was a high degree of positive
correlation between the two parameters. At ﬁrst this may appear para-
doxical, as hypermethylation of the promoter region serves as a repres-
sive epigenetic mark that down-regulates gene expression. However,
the methylated regions of SHOX2 were located in the gene body and
previous studies as well as a recent one by us have noted that gene
bodymethylation,which ismore prevalent in the genome thanpromot-
er hypermethylation,may be associatedwith increased gene expression
(Jones, 2012;Wang et al., 2016). Multiple recent studies have highlight-
ed the importance and promise of using molecular markers for LGG
prognosis and potentially as aids for therapeutic selection (Cancer
Genome Atlas Research et al., 2015; Eckel-Passow et al., 2015; Turkalp
et al., 2014; Dimitrov et al., 2015; Ceccarelli et al., 2016). To date, IDH
mutation status has been themost widely accepted and powerful prog-
nostic factor, either alone or in combination with other factors. In this
study, we identiﬁed that SHOX2methylation or expression were potent
independent prognostic indicator comparable to IDH for LGG patient
survival.We used the TCGA dataset as our training set and six additionaln for LGG patients (TCGA LGG dataset).
SHOX2 expression
p Value Hazard ratio (95% CI) p Value
0.0194 3.38 (2.25 to 5.09) 5.12E-09
6.97E-11 1.05 (1.04 to 1.07) 7.88E-10
0.4778 1.30 (0.90 to 1.87) 0.1641
0.0757 0.83 (0.51 to 1.34) 0.4451
0.0019 0.53 (0.34 to 0.81) 0.0036
0.0007 2.24 (1.47 to 3.41) 0.0002
dendroglioma.
Markers Compared Variable Events/Patients HR (95% CI) p value 
SHOX2_alone SHOX2 mRNA: high vs low 51/101 vs 75/414 3.38 (2.25 to 5.09) 5.12E-09
IDH_alone IDH: wt vs mut 50/94 vs 74/418 3.82 (2.47 to 5.90) 1.44E-09
SHOX2_vs_IDH SHOX2 mRNA: high vs low 51/101 vs 75/414 2.64 (1.61 to 4.34) 0.0001
SHOX2_vs_1p/19q SHOX2 mRNA: high vs low 51/101 vs 75/414 2.87 (1.87 to 4.39) 1.27E-06
SHOX2_vs_TERT(promoter) SHOX2 mRNA: high vs low 51/101 vs 75/414 2.99 (1.63 to 5.46) 0.0004
SHOX2_vs_MGMT SHOX2 mRNA: high vs low 51/101 vs 75/414 3.08 (2.01 to 4.71) 2.09E-07
SHOX2_vs_TERT(expression) SHOX2 mRNA: high vs low 51/101 vs 75/414 3.34 (2.20 to 5.06) 1.31E-08
SHOX2_vs_NES SHOX2 mRNA: high vs low 51/101 vs 75/414 3.40 (2.25 to 5.14) 7.21E-09
SHOX2_vs_ATRX SHOX2 mRNA: high vs low 51/101 vs 75/414 3.91 (2.50 to 6.10) 2.06E-09
IDH_vs_SHOX2 IDH: wt vs mut 50/94 vs 74/418 2.53 (1.52 to 4.20) 0.0003
1p/19q_vs_SHOX2 1p/19q: non -code vs codel 104/346 vs 22/169 2.30 (1.30 to 4.06) 0.0042
TERT(promoter)_vs_SHOX2 TERT promoter: mut vs wt 39/130 vs 35/162 1.09 (0.59 to 2.01) 0.7887
MGMT_vs_SHOX2 MGMT: unmethylated vs methylated 39/90 vs 87/425 1.82 (1.20 to 2.76) 0.0048
TERT(expression)_vs_SHOX2 TERT mRNA: Not_Expressed vs Expressed 67/288 vs 59/224 0.94 (0.61 to 1.44) 0.7632
NES_vs_SHOX2 NES mRNA: high vs low 68/255 vs 58/260 1.34 (0.93 to 1.93) 0.1189
ATRX_vs_SHOX2 ATRX: wt vs mut 79/325 vs45/187 0.96 (0.61 to 1.51) 0.8540
0 1 2 3 4 5 6 7 8
H R + 9 5 % C I
Fig. 9. Forest plot of themultivariate Cox proportional-hazardsmodel survival analyses of SHOX2 expressionmarker alone or in combination with other markers for LGG patients in TCGA
LGG dataset. This ﬁgure presented a summary of themultivariate analyses of SHOX2 expressionmarker alone, or SHOX2 co-presencewith one of other markers (NES,MGMT, TERT, 1p/19q
and ATRX) after adjusting for the same clinical variables described in Table 1. The names in the ﬁrst left column referred to the two markers (before or after “vs”) compared in the same
multivariate analyses, in which the analyzed result for the marker placed before “vs”was presented in the same row in the right columns. The cutoff value of SHOX2 RNA-Seq expression
data (4.135) was used to determine SHOX2 expression high vs low. HR: hazard ratio.
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While SHOX2 expression and gene bodymethylationwere highly corre-
lated, expression appeared to be the better prognostic marker and its
data weremore readily available. Thus we used expression for most ad-
ditional studies. Importantly, we found that the combination of SHOX2
and IDH status identiﬁed a subset of IDHwt LGG with a considerably
improved survival time. Of interest, another study utilizing molecular
proﬁling indicated the presence of a subtype with improved prognosis
(Ceccarelli et al., 2016). Conceivably, SHOX2 status can be determined
by standard molecular assays such as PCR in a routine laboratory,
which is clinically attractive.
We further investigated the combination of SHOX2 with other
known clinically relevant markers of LGG including TERT, 1p/19q,
MGMT, ATRX and NES, and found that SHOX2 was a potent indicator to
identify subsets of LGG with signiﬁcant better survivals especially in
the worse prognosis subgroup determined by individual markers. Our
study demonstrated that SHOX2 not only is an independent potent
prognostic marker, but also has potential to reﬁne the molecular classi-
ﬁcation of LGG in combinationwith other well establishedmarkers. The
addition of SHOX2 expression identiﬁes small but highly signiﬁcant sub-
groups having good prognosis within the poor prognosis groups identi-
ﬁed by IDH mutation status and several other commonly used
prognostic markers. Thus, therapy options for these subgroups may be
altered as a result of our observations, although prospective studies
will be required to prove this. Finally, we demonstrated by multivariate
survival analysis that SHOX2 was a potent survival prognosis marker
comparable to IDH after adjusting for age and other clinical variables
and signiﬁcantly different from all the other markers mentioned above.
Asmentioned previously, SHOX2mayplay a prognostic role in breast
and hepatocellular carcinomas (Yang et al., 2013; Hong et al., 2014).
SHOX2 was suggested to be a novel epithelial-to-mesenchymal
transition inducer in breast cancer cells (Hong et al., 2014), and overex-
pression of SHOX2 was able to induce canine mesenchymal stem cell
differentiation into native pacemaker cells (Feng et al., 2016). We ob-
served an upward trend of SHOX2 aberrant hypermethylation and
expression from clinically benign pilocytic astrocytomas, intermediatemalignant LGG to high malignant GBM. This is in contrast to IDH
mutations which are largely limited to LGG and only occasionally
present in primary GBM (Yan et al., 2009). However, SHOX2 expression
was not found to have prognostic signiﬁcance in the TCGA GBM dataset
in this study, possibly because most GBM tumors have high SHOX2
expression. Our current ﬁndings suggest a potential oncogenic role of
SHOX2 in glioma tumors, although the precise mechanism is largely
unknown.
In conclusion, we have identiﬁed that SHOX2 expression or methyl-
ation are potent independent prognostic indicators for predicting LGG
patient survival, and have potential to identify an important subset of
LGG patients with IDHwt status with signiﬁcantly better overall
survival. The combination of IDH or other relevant markers with
SHOX2 identiﬁed LGG subsets with signiﬁcantly different survival out-
comes, and further understanding of these subsets may beneﬁt
therapeutic target identiﬁcation and therapy selections for glioma
patients.
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